Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon Merims

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Pediatric Dermatology|April 22, 2020
Subcutaneous granuloma annulare mimicking dermatomyositisKarin Maoz, Shoshana Greenberger, Alexander Maly, et al.
Plos One|April 14, 2020
Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patientsNir Hirshoren, Roni Yoeli, Jonathan E Cohen, et al.
The British Journal of Dermatology|August 28, 2022
Giant congenital melanocytic naevus with a novel CUX1-BRAF fusion mutation treated with trametinibVered Molho-Pessach, Stav Hartshtark, Sharon Merims, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 30, 2013
Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cellsGalit Eisenberg, Ronny Uzana, Aviad Pato, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 14, 2011
Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8+ T cell clonesRonny Uzana, Galit Eisenberg, Yael Sagi, et al.
International Journal of Dermatology|January 31, 2016
Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinicAyelet Ollech, Salomon M Stemmer, Sharon Merims, et al.
Plos One|February 12, 2015
Human T cell crosstalk is induced by tumor membrane transferRonny Uzana, Galit Eisenberg, Sharon Merims, et al.
Dermatologic Therapy|October 3, 2022
Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanomaRony Shreberk-Hassidim, Lilach Aizenbud, Shalev Lussheimer, et al.
Frontiers in Oncology|March 3, 2020
Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective StudyReut Hadash-Bengad, Emma Hajaj, Shiri Klein, et al.
Science Translational Medicine|June 7, 2023
Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactionsNethanel Friedman, Liza Weinstein-Fudim, Yelena Mostinski, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Pediatric Dermatology|April 22, 2020
Subcutaneous granuloma annulare mimicking dermatomyositisKarin Maoz, Shoshana Greenberger, Alexander Maly, et al.
Plos One|April 14, 2020
Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patientsNir Hirshoren, Roni Yoeli, Jonathan E Cohen, et al.
The British Journal of Dermatology|August 28, 2022
Giant congenital melanocytic naevus with a novel CUX1-BRAF fusion mutation treated with trametinibVered Molho-Pessach, Stav Hartshtark, Sharon Merims, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 30, 2013
Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cellsGalit Eisenberg, Ronny Uzana, Aviad Pato, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 14, 2011
Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8+ T cell clonesRonny Uzana, Galit Eisenberg, Yael Sagi, et al.
International Journal of Dermatology|January 31, 2016
Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinicAyelet Ollech, Salomon M Stemmer, Sharon Merims, et al.
Plos One|February 12, 2015
Human T cell crosstalk is induced by tumor membrane transferRonny Uzana, Galit Eisenberg, Sharon Merims, et al.
Dermatologic Therapy|October 3, 2022
Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanomaRony Shreberk-Hassidim, Lilach Aizenbud, Shalev Lussheimer, et al.
Frontiers in Oncology|March 3, 2020
Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma-A Retrospective StudyReut Hadash-Bengad, Emma Hajaj, Shiri Klein, et al.
Science Translational Medicine|June 7, 2023
Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactionsNethanel Friedman, Liza Weinstein-Fudim, Yelena Mostinski, et al.
Pageof 3